<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Idorsia Ltd — News on 6ix</title>
    <link>https://6ix.com/company/idorsia-ltd</link>
    <description>Latest news and press releases for Idorsia Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 05:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/idorsia-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68361b5878dffbe2df13f23a.webp</url>
      <title>Idorsia Ltd</title>
      <link>https://6ix.com/company/idorsia-ltd</link>
    </image>
    <item>
      <title>Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-reports-strong-q1-2026-performance-with-74percent-quviviq-sales-growth-year-on-year</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-reports-strong-q1-2026-performance-with-74percent-quviviq-sales-growth-year-on-year</guid>
      <pubDate>Tue, 28 Apr 2026 05:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next stepsCo-promotion of QUVIVIQ is being expanded across additional European markets to further accelerate growthPartnering discussions for TRYVIO™/JERAYGO™ are ongoing with several parties Allschwil, Switzerland – April 28, 2026Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-cl</description>
    </item>
    <item>
      <title>Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-issues-invitation-to-the-2026-annual-general-meeting-of-shareholders</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-issues-invitation-to-the-2026-annual-general-meeting-of-shareholders</guid>
      <pubDate>Fri, 10 Apr 2026 05:00:00 GMT</pubDate>
      <description>Allschwil, Switzerland – April 10, 2026Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2025, will be held on Wednesday, May 6, 2026, at 14.00 CEST at the Congress Center, Messe Basel, Switzerland. Notes to ShareholdersThe invitation was published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt) t</description>
    </item>
    <item>
      <title>Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-welcomes-amer-joseph-as-new-chief-medical-officer-and-head-of-global-clinical-development</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-welcomes-amer-joseph-as-new-chief-medical-officer-and-head-of-global-clinical-development</guid>
      <pubDate>Thu, 09 Apr 2026 05:00:00 GMT</pubDate>
      <description>Idorsia thanks Alberto Gimona – most recently Head of Global Clinical Development and Medical Affairs – and wishes him all the best for a well-deserved retirementAmer Joseph joins Idorsia as EVP, Chief Medical Officer &amp; Head of Global Clinical Development, becoming a member of the Idorsia Executive Committee Allschwil, Switzerland – April 9, 2026Idorsia Ltd (SIX: IDIA) announces the appointment of Dr Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) &amp; Head of Global Clinical D</description>
    </item>
    <item>
      <title>Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsias-daridorexant-delivers-outstanding-results-in-a-phase-2-study-in-children-with-insomnia-disorder</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsias-daridorexant-delivers-outstanding-results-in-a-phase-2-study-in-children-with-insomnia-disorder</guid>
      <pubDate>Mon, 30 Mar 2026 05:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep measures in children with insomnia disorder, with especially pronounced efficacy in those with co-morbid neurodevelopmental disordersExcellent safety and tolerability of daridorexant confirmed for the first time in a pediatric population – including at the highest dose testedIdorsia to engage with hea</description>
    </item>
    <item>
      <title>Idorsia announces the nomination of three candidates for election to the Board of Directors</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-announces-the-nomination-of-three-candidates-for-election-to-the-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-announces-the-nomination-of-three-candidates-for-election-to-the-board-of-directors</guid>
      <pubDate>Tue, 24 Mar 2026 06:00:00 GMT</pubDate>
      <description>Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting 2026 on May 6, 2026All Board members – current and proposed – are committed to accelerating the growth of the company Allschwil, Switzerland – March 24, 2026Idorsia Ltd (SIX: IDIA) announces that the Board of Directors will propose three candidates for election to the Board at the upcoming Annual General Meeting of Shareholders: Natalia M</description>
    </item>
    <item>
      <title>Idorsia announces management change</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-announces-management-change</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-announces-management-change</guid>
      <pubDate>Mon, 16 Mar 2026 06:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 16, 2026Idorsia Ltd (SIX: IDIA) announces that Dr Srishti Gupta and the Board of Idorsia have mutually agreed that Srishti will step down from her role as Chief Executive Officer (CEO). She will also step down from the Board of Directors. The Board has initiated the search process to identify a new CEO. Until a successor is appointed, the Board will collectively support the experienced management team in place. Jean-Paul C</description>
    </item>
    <item>
      <title>Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-expands-quviviqs-global-footprint-through-new-partnership-with-pharmalink</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-expands-quviviqs-global-footprint-through-new-partnership-with-pharmalink</guid>
      <pubDate>Tue, 10 Mar 2026 06:00:00 GMT</pubDate>
      <description>Idorsia and Pharmalink enter into an exclusive distribution and commercialization agreement for QUVIVIQ™ (daridorexant) in the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain Allschwil, Switzerland – March 10, 2026Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Pharmalink Drug Store L.L.C for the distribution and commercialization of QUVIVIQ™ (daridorexant) – its treatment for adults with insomnia – across the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and</description>
    </item>
    <item>
      <title>Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-reports-strong-2025-results-with-quviviq-sales-more-than-doubling-further-sales-growth-ahead-with-multiple-pipeline-catalysts-in-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-reports-strong-2025-results-with-quviviq-sales-more-than-doubling-further-sales-growth-ahead-with-multiple-pipeline-catalysts-in-2026</guid>
      <pubDate>Thu, 26 Feb 2026 06:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR Idorsia delivers on its upgraded 2025 guidance, with strong QUVIVIQ sales growth, disciplined investment, and a significantly improved bottom line.Focused investment in Idorsia’s pipeline of first-in-class medicines to drive future growth, with key readout for daridorexant in pediatric insomnia imminent and Lucerastat registration study advancing in Fabry’s disease. Allschwil, Switzerland – February 26, 2026Idorsia Ltd (SIX: IDIA) announces strong finan</description>
    </item>
    <item>
      <title>Invitation to Idorsia&apos;s FY 2025 Financial Reporting webcast and conference call</title>
      <link>https://6ix.com/company/idorsia-ltd/news/invitation-idorsias-fy-2025-financial-164500899</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/invitation-idorsias-fy-2025-financial-164500899</guid>
      <pubDate>Thu, 12 Feb 2026 16:45:00 GMT</pubDate>
      <description>Idorsia will publish its Full Year 2025 Financial Reporting on Thursday February 26, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day. Date: Thursday, February 26, 2026 Time: 14:00 CET / 13:00 GMT / 08:00 EST The call will start with presentations by senior management, followed by a Q&amp;A session. Live Webcast (audio + slides):The live webcast can be accessed from the Idorsia website www.idorsia.com. Dial-in procedure for analysts (audio onl</description>
    </item>
    <item>
      <title>Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease</title>
      <link>https://6ix.com/company/idorsia-ltd/news/clear-route-registration-positions-lucerastat-060000386</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/clear-route-registration-positions-lucerastat-060000386</guid>
      <pubDate>Fri, 06 Feb 2026 06:00:00 GMT</pubDate>
      <description>Allschwil, Switzerland – February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker and renal findings from the MODIFY Phase 3 trial and its long‑term open-label extension (OLE), the program focuses on lucerastat’s impact on renal pathology – a central driver of morbidity and mortality in Fabry disease – with the goal of securing market authorization. Fabry disease is a rare, X-lin</description>
    </item>
    <item>
      <title>Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-present-long-term-lucerastat-060000995</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-present-long-term-lucerastat-060000995</guid>
      <pubDate>Fri, 30 Jan 2026 06:00:00 GMT</pubDate>
      <description>Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is finalizing the development plan for the optimal regulatory pathway to approval Allschwil, Switzerland – January 30, 2026Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORLDSymposium™, taking place fr</description>
    </item>
    <item>
      <title>Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America</title>
      <link>https://6ix.com/company/idorsia-ltd/news/global-expansion-idorsia-quviviq-continues-060000015</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/global-expansion-idorsia-quviviq-continues-060000015</guid>
      <pubDate>Wed, 28 Jan 2026 06:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026Idorsia Ltd (SIX: IDIA) announces an exclusive license and supply agreement with EMS S.A., Brazil’s largest privately-owned pharmaceutical company, to bring QUVIVIQ™ (daridorexant) to patients across Latin America. This partnership marks another milestone in Idorsia’s mission to make QUVIVIQ available worldwide</description>
    </item>
    <item>
      <title>Idorsia to present at J.P. Morgan 2026 Healthcare Conference</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-present-j-p-morgan-060000065</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-present-j-p-morgan-060000065</guid>
      <pubDate>Mon, 12 Jan 2026 06:00:00 GMT</pubDate>
      <description>Allschwil, Switzerland – January 12, 2026Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 10:30 am PST / 7:30 pm CET. The conference will take place at the Westin St. Francis hotel in San Francisco, USA. Dr Gupta will share how, with two products entering value-acceleration phase and an innovative pipeline poised to deliver the next generations of brea</description>
    </item>
    <item>
      <title>Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease</title>
      <link>https://6ix.com/company/idorsia-ltd/news/nature-communications-reports-promising-effect-055500556</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/nature-communications-reports-promising-effect-055500556</guid>
      <pubDate>Mon, 12 Jan 2026 05:55:00 GMT</pubDate>
      <description>In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying effectThe company is working with health authorities to find the optimal pathway to approval Allschwil, Switzerland – January 12, 2026Idorsia Ltd (SIX: IDIA) announces the publication of results from the pivotal Phase 3 MODIFY study and its open-label extension (OLE) evaluating lucerastat, an oral su</description>
    </item>
    <item>
      <title>Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-initiates-proof-concept-trial-060000547</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-initiates-proof-concept-trial-060000547</guid>
      <pubDate>Tue, 06 Jan 2026 06:00:00 GMT</pubDate>
      <description>The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications Allschwil, Switzerland – January 6, 2026Idorsia Ltd (SIX: IDIA) announces the initiation of a Phase 2 proof-of-concept trial evaluating IDOR-1117-2520 for participants with moderate-to-severe psoriasis. IDOR-1117-2520 is Idorsia’s first-in-class, oral, selective CCR6 receptor antagonist designed to block the CCR6/CCL20 axis and prevent the migration</description>
    </item>
    <item>
      <title>Idorsia’s daridorexant in women during menopausal transition age with insomnia</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-daridorexant-women-during-menopausal-164500785</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-daridorexant-women-during-menopausal-164500785</guid>
      <pubDate>Mon, 05 Jan 2026 16:45:00 GMT</pubDate>
      <description>New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition ageBrigham and Women’s Hospital to study the effectiveness and safety of daridorexant for menopause-related insomnia symptoms Allschwil, Switzerland – January 5, 2026Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal transition</description>
    </item>
    <item>
      <title>Idorsia’s JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-jeraygo-aprocitentan-approved-canada-060000830</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-jeraygo-aprocitentan-approved-canada-060000830</guid>
      <pubDate>Mon, 05 Jan 2026 06:00:00 GMT</pubDate>
      <description>Idorsia receives approval from Health Canada for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO is a new oral antihypertensive therapy – the first systemic hypertension treatment to target a new pathway in over 30 years. Allschwil, Switzerland – January 5, 2026Idorsia Ltd (SIX: IDIA) announces that Health Canada has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hyp</description>
    </item>
    <item>
      <title>New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD</title>
      <link>https://6ix.com/company/idorsia-ltd/news/hypertension-publication-underscores-aprocitentan-potential-060000002</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/hypertension-publication-underscores-aprocitentan-potential-060000002</guid>
      <pubDate>Wed, 10 Dec 2025 06:00:00 GMT</pubDate>
      <description>New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population with difficult-to-control hypertension Allschwil, Switzerland – December 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant</description>
    </item>
    <item>
      <title>Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology &amp; Pharmaceutical Product’ category</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-treatment-insomnia-disorder-wins-164500666</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-treatment-insomnia-disorder-wins-164500666</guid>
      <pubDate>Tue, 09 Dec 2025 16:45:00 GMT</pubDate>
      <description>Idorsia’s dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of insomnia disorder, has been awarded the inaugural Prix Galien Bridges Award in the category of “Best Biotechnology &amp; Pharmaceutical Product”Inaugural winners are honored for breakthrough innovations in life sciences Allschwil, Switzerland – December 9, 2025Idorsia Ltd (SIX: IDIA) announces that its novel treatment for insomnia disorder has been awarded the inaugural Prix Galien</description>
    </item>
    <item>
      <title>Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension</title>
      <link>https://6ix.com/company/idorsia-ltd/news/idorsia-aprocitentan-improved-key-prognostic-164500147</link>
      <guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-aprocitentan-improved-key-prognostic-164500147</guid>
      <pubDate>Mon, 10 Nov 2025 16:45:00 GMT</pubDate>
      <description>New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of aprocitentan’s novel endothelin pathway mechanism in addressing significant medical need in difficult-to-control hypertension Allschwil, Switzerland – November 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in the Journal of Hypert</description>
    </item>
  </channel>
</rss>